By Associate Professor Behzad Hajarizadeh

Journal articles

Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002

Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204

Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422

Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B, 2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, 28, pp. 1340 - 1354, http://dx.doi.org/10.1111/jvh.13574

Ahmadi O; Das M; Hajarizadeh B; Mathy JA, 2021, 'Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis', Annals of Surgical Oncology, 28, pp. 6168 - 6176, http://dx.doi.org/10.1245/s10434-021-09866-3

Grebely J; Collins AB; Artenie AA; Sutherland R; Meyer JP; Barocas JA; Falade-Nwulia O; Cepeda JA; Cunningham EB; Hajarizadeh B; Lafferty L; Lazarus JV; Bonn M; Marshall AD; Treloar C, 2021, 'Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103469

Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT, 2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', PLoS ONE, 16, http://dx.doi.org/10.1371/journal.pone.0257369

Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B, 2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 73, pp. E107 - E118, http://dx.doi.org/10.1093/cid/ciaa612

Ferraro CF; Stewart DE; Grebely J; Tran LT; Zhou S; Puca C; Hajarizadeh B; Larney S; Santo T; Higgins JPT; Vickerman P; Degenhardt L; Hickman M; French CE, 2021, 'Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis', Addiction, 116, pp. 1664 - 1676, http://dx.doi.org/10.1111/add.15316

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Loveday S; Tamaddoni M; Obeid S; Estivill Mercade G; Martinez M; Donnelly R; Bowman J; Trevethan L; Lagios K; Murrell T; Bath N; Tawil V; Stevens A; Topp L; Churchill A; Pinnock K; Drew S; Harrod M; Smith A; Williams R; Cooper B; Somes K; Burns C; Kaur A; Lobo C; Conroy K; McCredie L; Café C; Anlezark J; Rawlinson W; Yeang M; Wynn M; Willenborg C, 2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, 6, pp. 533 - 546, http://dx.doi.org/10.1016/S2468-1253(21)00077-7

Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival', Journal of Viral Hepatitis, 28, pp. 710 - 718, http://dx.doi.org/10.1111/jvh.13475

Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253

Catlett B; Bajis S; Starr M; Dore GJ; Hajarizadeh B; Cunningham PH; Applegate TL; Grebely J, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, 223, pp. 818 - 826, http://dx.doi.org/10.1093/infdis/jiaa442

Applegate T; Bajis S; Catlett B; Cunningham P; Dore G; Grebely J; Hajarizadeh B, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, http://dx.doi.org/10.1093/infdis/jiaa442

Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038

Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089

Dore G; Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Mcmanus H; Butler T; Vickerman P; Martin N; Mchutchison J; Brainard D; Treloar C; Lloyd A, 2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, 73, pp. S127 - S127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587000206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL, 2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037

Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101

Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633

Martinello M; Hajarizadeh B; Dore GJ, 2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012

Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K; Grebely J; Applegate T; Read P; Hajarizadeh B; Ezard N; Dore G; Edwards M, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233

He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598

Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196

Moradi G; Hajarizadeh B; Rahmani K; Mohamadi-Bolbanabad A; Darvishi S; Zareie B; Zavareh FA; Sharafi H; Alavian SM; Ramazani R; Eftekhar M; Radfar SR; Piroozi B; Gouya MM, 2019, 'Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran', International Journal of Drug Policy, 73, pp. 129 - 134, http://dx.doi.org/10.1016/j.drugpo.2019.09.018

Wallace J; Smith E; Hajarizadeh B; Richmond J; Lucke J, 2019, 'Addressing cultural diversity: the hepatitis B clinical specialist perspective', Ethnicity and Health, 24, pp. 816 - 828, http://dx.doi.org/10.1080/13557858.2017.1370540

Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002

Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C, 2019, 'Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all', International Journal of Drug Policy, 72, pp. 1 - 10, http://dx.doi.org/10.1016/j.drugpo.2019.07.016

Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014

Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112

Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010

Major M; Gutfraind A; Shekhtman L; Cui Q; Kachko A; Cotler SJ; Hajarizadeh B; Sacks-Davis R; Page K; Boodram B; Dahari H, 2018, 'Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users', Science Translational Medicine, 10, http://dx.doi.org/10.1126/scitranslmed.aao4496

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5

Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, 32, pp. 269 - 279, http://dx.doi.org/10.1016/j.idc.2018.02.006

Razavi-Shearer D; Gamkrelidze I; Nguyen MH; Chen DS; Van Damme P; Abbas Z; Abdulla M; Abou Rached A; Adda D; Aho I; Akarca U; Al Ali FH; Lawati FAL; Naamani KAL; Alashgar HI; Alavian SM; Alawadhi S; Albillos A; Al-Busafi SA; Aleman S; Alfaleh FZ; Aljumah AA; Anand AC; Anh NT; Arends JE; Arkkila P; Athanasakis K; Bane A; Ben-Ari Z; Berg T; Bizri AR; Blach S; Brandão Mello CE; Brandon SM; Bright B; Bruggmann P; Brunetto M; Buti M; Chan HLY; Chaudhry A; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Clausen MR; Colombo M; Cornberg M; Cowie B; Craxi A; Croes EA; Cuellar DA; Cunningham C; Desalegn H; Drazilova S; Duberg AS; Egeonu SS; El-Sayed MH; Estes C; Falconer K; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gaeta GB; García-Samaniego J; Genov J; Gerstoft J; Goldis A; Gountas I; Gray R; Guimarães Pessôa M; Hajarizadeh B; Hatzakis A; Hézode C; Himatt SM; Hoepelman A; Hrstic I; Hui YTT; Husa P; Jahis R; Janjua NZ; Jarcuška P; Jaroszewicz J; Kaymakoglu S; Kershenobich D; Kondili LA; Konysbekova A; Krajden M; Kristian P; Laleman W; Lao WCC; Layden J; Lazarus JV; Lee MH; Liakina V; Lim YSS; Loo CKK; Lukšic B; Malekzadeh R, 2018, 'Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study', The Lancet Gastroenterology and Hepatology, 3, pp. 383 - 403, http://dx.doi.org/10.1016/S2468-1253(18)30056-6

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852

Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114

Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, 18, http://dx.doi.org/10.1186/s12879-018-3110-0

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019

Back to profile page